AC-699 is under clinical development by Accutar Biotechnology and currently in Phase I for Metastatic Breast Cancer. According to GlobalData, Phase I drugs for Metastatic Breast Cancer have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AC-699’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AC-699 overview

AC-699 is under development for the treatment of estrogen receptor positive or human epidermal growth factor receptor 2 negative locally advanced or metastatic breast cancer. The drug candidate is an orally bioavailable estrogen receptor degrader.

Accutar Biotechnology overview

Accutar Biotechnology (Accutar Biotech) is a biotechnology company that employs artificial intelligence to revolutionize drug discovery. It is headquartered in Brooklyn, New York, the US.

For a complete picture of AC-699’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.